ENO2 and neuroblastoma: Chauhan et al. [24] have pointed out that about 69% of SCLC patients have a higher serum NSE level, and the changes in this index are related to the occurrence of multiple tumors such as medullary thyroid carcinoma, neuroblastoma, and melanoma.